Critical role of glutathione in melatonin enhancement of tumor necrosis factor and ionizing radiation-induced apoptosis in prostate cancer cells in vitro

Journal of Pineal Research

Volumn 45, Issue 3, 2008, Pages 258-270

  Sainz, Rosa M ^a   Reiter, Russel J ^b   Tan, Dun Xian ^b   Roldan, Francis ^c   Natarajan, Mohan ^c   Quiros, Isabel ^a   Hevia, David ^a   Rodriguez, Carmen ^a   Mayo, Juan C ^a  

^a DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^b Department of Cellular and Structural Biology ^*

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Apoptosis; Glutathione; Melatonin; NF B; Prostate cancer

Indexed keywords

GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELATONIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL DEATH; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IONIZING RADIATION; PROSTATE CANCER;

ANALYSIS OF VARIANCE; ANTIOXIDANTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GLUTATHIONE; GLUTATHIONE DISULFIDE; HUMANS; MALE; MELATONIN; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NF-KAPPA B P50 SUBUNIT; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIATION, IONIZING; REACTIVE OXYGEN SPECIES; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 51649104989     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2008.00585.x     Document Type: Article

References (61)

1. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005 55: 10 30.
2. Ross RK, Pike MC, Coetzee GA et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 1998 58: 4497 4504.
3. Zi X, Agarwal R. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proc Natl Acad Sci U S A 1999 96: 7490 7495.
4. Greenlee RT, Murray T, Bolden S et al. Cancer statistics, 2000. CA Cancer J Clin 2000 50: 7 33.
5. Krajewska M, Krajewski S, Banares S et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 2003 9: 4914 4925.
6. Palayoor ST, Youmell MY, Calderwood SK et al. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999 18: 7389 7394.
7. Borek C. Dietary antioxidants and human cancer. Integr Cancer Ther 2004 3: 333 341.
8. Bowie A, O'Neill LA. Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries. Biochem Pharmacol 2000 59: 13 23.
9. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D et al. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001 20: 7597 7609.
10. Fulda S, Debatin KM. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 2004 64: 337 346.
11. Hastak K, Agarwal MK, Mukhtar H et al. Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate. FASEB J 2005 19: 789 791.
12. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991 12: 151 180.
13. Tan DX, Manchester LC, Hardeland R et al. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res 2003 34: 75 78.
14. Reiter RJ, Tan DX, Sainz RM et al. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 2002 54: 1299 1321.
15. Schernhammer ES, Laden F, Speizer FE et al. Night-shift work and risk of colorectal cancer in the nurses' health study. J Natl Cancer Inst 2003 95: 825 828.
16. Schernhammer ES, Laden F, Speizer FE et al. Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J Natl Cancer Inst 2001 93: 1563 1568.
17. Blask DE, Dauchy RT, Sauer LA et al. Light during darkness, melatonin suppression and cancer progression. Neuro Endocrinol Lett 2002 23 (Suppl. 2 52 56.
18. Dauchy RT, Blask DE, Sauer LA et al. Dim light during darkness stimulates tumor progression by enhancing tumor fatty acid uptake and metabolism. Cancer Lett 1999 144: 131 136.
19. Reiter RJ. Mechanisms of cancer inhibition by melatonin. J Pineal Res 2004 37: 213 214.
20. Sainz RM, Mayo JC, Tan DX et al. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate 2005 63: 29 43.
21. Mohan N, Sadeghi K, Reiter RJ et al. The neurohormone melatonin inhibits cytokine, mitogen and ionizing radiation induced NF-kappa B. Biochem Mol Biol Int 1995 37: 1063 1070.
22. Lissoni P, Barni S, Mandala M et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 1999 35: 1688 1692.
23. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989 119: 203 210.
24. Wang H, Joseph JA. Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radic Biol Med 1999 27: 612 616.
25. Mayo JC, Tan DX, Sainz RM et al. Protection against oxidative protein damage induced by metal-catalyzed reaction or alkylperoxyl radicals: comparative effects of melatonin and other antioxidants. Biochim Biophys Acta 2003 1620: 139 150.
26. Saldeen J, Welsh N. Nicotinamide-induced apoptosis in insulin producing cells is associated with cleavage of poly(ADP-ribose) polymerase. Mol Cell Endocrinol 1998 139: 99 107.
27. Griffith OW. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 1980 106: 207 212.
28. Sainz RM, Mayo JC, Tan DX et al. Antioxidant activity of melatonin in Chinese hamster ovarian cells: changes in cellular proliferation and differentiation. Biochem Biophys Res Commun 2003 302: 625 634.
29. Suh J, Rabson AB. NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? J Cell Biochem 2004 91: 100 117.
30. Fojo T, Bates S. Strategies for reversing drug resistance. Oncogene 2003 22: 7512 7523.
31. Gille JJ, Van Berkel CG, Joenje H. Mutagenicity of metabolic oxygen radicals in mammalian cell cultures. Carcinogenesis 1994 15: 2695 2699.
32. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003 3: 276 285.
33. Menon SG, Sarsour EH, Spitz DR et al. Redox regulation of the G1 to S phase transition in the mouse embryo fibroblast cell cycle. Cancer Res 2003 63: 2109 2117.
34. Blask DE, Sauer LA, Dauchy RT et al. Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events. Cancer Res 1999 59: 4693 4701.
35. Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005 27: 101 110.
36. Collins A, Yuan L, Kiefer TL et al. Overexpression of the MT1 melatonin receptor in MCF-7 human breast cancer cells inhibits mammary tumor formation in nude mice. Cancer Lett 2003 189: 49 57.
37. Dillon DC, Easley SE, Asch BB et al. Differential expression of high-affinity melatonin receptors (MT1) in normal and malignant human breast tissue. Am J Clin Pathol 2002 118: 451 458.
38. Ram PT, Dai J, Yuan L et al. Involvement of the mt1 melatonin receptor in human breast cancer. Cancer Lett 2002 179: 141 150.
39. Moretti RM, Marelli MM, Maggi R et al. Antiproliferative action of melatonin on human prostate cancer LNCaP cells. Oncol Rep 2000 7: 347 351.
40. Ripple MO, Henry WF, Schwarze SR et al. Effect of antioxidants on androgen-induced AP-1 and NF-kappaB DNA-binding activity in prostate carcinoma cells. J Natl Cancer Inst 1999 91: 1227 1232.
41. Kampa M, Hatzoglou A, Notas G et al. Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines. Nutr Cancer 2000 37: 223 233.
42. Bromfield GP, Meng A, Warde P et al. Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill. Prostate Cancer Prostatic Dis 2003 6: 73 85.
43. Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 2005 65: 3980 3985.
44. Mediavilla MD, Cos S, Sanchez-Barcelo EJ. Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci 1999 65: 415 420.
45. Agarwal C, Sharma Y, Agarwal R. Anticarcinogenic effect of a polyphenolic fraction isolated from grape seeds in human prostate carcinoma DU145 cells: modulation of mitogenic signaling and cell-cycle regulators and induction of G1 arrest and apoptosis. Mol Carcinog 2000 28: 129 138.
46. Gunawardena K, Murray DK, Meikle AW. Vitamin E and other antioxidants inhibit human prostate cancer cells through apoptosis. Prostate 2000 44: 287 295.
47. Jeon KI, Rih JK, Kim HJ et al. Pretreatment of indole-3-carbinol augments TRAIL-induced apoptosis in a prostate cancer cell line, LNCaP. FEBS Lett 2003 544: 246 251.
48. Manda K, Ueno M, Anzai K. AFMK, a melatonin metabolite, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice. J Pineal Res 2007 42: 386 393.
49. Tan DX, Manchester LC, Terron MP et al. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007 42: 28 42.
50. Rosen J, Than NN, Koch D et al. Interactions of melatonin and its metabolites with the ABTS cation radical: extension of the radical scavenger cascade and formation of a novel class of oxidation products, C2-substituted 3-indolinones. J Pineal Res 2006 41: 374 381.
51. Vijayalaxmi, Reiter RJ, Tan DX et al. Melatonin as a radioprotective agent: a review. Int J Radiat Oncol Biol Phys 2004 59: 639 653.
52. Lissoni P, Paolorossi F, Tancini G et al. Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 1996 32A: 1340 1343.
53. Sumitomo M, Tachibana M, Nakashima J et al. An essential role for nuclear factor kappa B in preventing TNF-alpha-induced cell death in prostate cancer cells. J Urol 1999 161: 674 679.
54. Aggarwal BB. Apoptosis and nuclear factor-kappa B: a tale of association and dissociation. Biochem Pharmacol 2000 60: 1033 1039.
55. Ricote M, Royuela M, Garcia-Tunon I et al. Pro-apoptotic tumor necrosis factor-alpha transduction pathway in normal prostate, benign prostatic hyperplasia and prostatic carcinoma. J Urol 2003 170: 787 790.
56. Mayo JC, Sainz RM, Antolin I et al. Melatonin regulation of antioxidant enzyme gene expression. Cell Mol Life Sci 2002 59: 1706 1713.
57. Blask DE, Wilson ST, Zalatan F. Physiological melatonin inhibition of human breast cancer cell growth in vitro: evidence for a glutathione-mediated pathway. Cancer Res 1997 57: 1909 1914.
58. Guo G, Yan-Sanders Y, Lyn-Cook BD et al. Manganese superoxide dismutase-mediated gene expression in radiation-induced adaptive responses. Mol Cell Biol 2003 23: 2362 2378.
59. Takada Y, Hachiya M, Park SH et al. Role of reactive oxygen species in cells overexpressing manganese superoxide dismutase: Mechanism for induction of radioresistance. Mol Cancer Res 2002 1: 137 146.
60. Wu G, Fang YZ, Yang S et al. Glutathione metabolism and its implications for health. J Nutr 2004 134: 489 492.
61. Chuang JI, Chang TY, Liu HS. Glutathione depletion-induced apoptosis of Ha-ras-transformed NIH3T3 cells can be prevented by melatonin. Oncogene 2003 22: 1349 1357.